Armata Pharmaceuticals, Inc. — Q1 2022 Form 10-Q
Business context and reporting period. This clinical-stage biotechnology company develops bacteriophage therapies for difficult-to-treat and antibiotic-resistant infections. The filing covers the three months ended March 31, 2022; financial statements are unaudited. Armata reported grant revenue, but no product sales.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Grant revenue | $1.236 million | $1.066 million |
| Research and development expense | $8.028 million | $4.350 million |
| General and administrative expense | $1.983 million | $2.151 million |
| Total operating expenses | $10.011 million | $6.501 million |
| Operating loss | $8.775 million | $5.435 million |
| Net loss | $8.774 million | $5.495 million |
| Basic and diluted loss per share | $0.30 | $0.27 |
| Net cash used in operating activities | $3.515 million | $5.475 million |
- Liquidity: At March 31, cash and cash equivalents were $46.408 million, with a further $5.960 million of restricted cash. Current assets were $48.699 million and current liabilities $6.226 million.
- Balance sheet: Total assets were $107.765 million, total liabilities $46.226 million, and stockholders’ equity $61.539 million. Operating lease liabilities totaled $38.443 million, including current and non-current portions; the filing reports no borrowings as financial debt.
- Cash flow and financing: Investing activities used $0.236 million. Financing activities provided $44.631 million, primarily from the Innoviva placement. Cash, cash equivalents and restricted cash increased by $40.880 million during the quarter.
- Margins: Product gross margin is not applicable; the company had no product sales. The filing does not provide a meaningful operating margin measure for this development-stage business.
Material changes versus prior comparable period
- R&D expense increased $3.678 million, primarily due to greater clinical-trial activity and outsourcing, personnel costs, and lease expense. Lower Australian tax-rebate credits partly offset the increase.
- Net loss widened by $3.279 million, while loss per share increased from $0.27 to $0.30. Weighted-average shares rose to 28.996 million from 20.458 million.
- Operating cash use declined by $1.960 million despite the higher net loss; changes in operating assets and liabilities affected the cash-flow comparison.
- Armata issued 9.0 million shares to Innoviva at $5 per share in two closings, receiving approximately $45 million gross proceeds and issuing warrants for up to 4.5 million additional shares at a $5 exercise price. Shares outstanding rose to 36.112 million from 27.112 million at year-end.
Outlook, commentary, risks and unusual items
- Management said existing resources were expected to fund planned operations into the first quarter of 2023. However, recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern; additional financing is needed and is not assured.
- The company expects significant operating losses to continue and does not expect product revenue until it develops a candidate and obtains marketing approval. No quantified earnings or revenue guidance is provided.
- FDA cleared the IND for AP-PA02 in non-cystic fibrosis bronchiectasis; Armata planned to start a Phase 2 trial in 2022. The company also planned to advance AP-PA02 in cystic fibrosis and AP-SA02 for S. aureus bacteremia, subject to enrollment and other development risks.
- COVID-19 had delayed clinical-trial site identification and initiation. Further enrollment, supply-chain, manufacturing, regulatory and financing effects remained uncertain. The company also cited potential supply-chain disruption, including from geopolitical events.
- A new Los Angeles lease carries a 16-year term, with rent commencement in May 2022, base monthly rent of approximately $0.25 million beginning in 2024, and a tenant-improvement allowance of up to $7.3 million. Construction costs, timing and reimbursement pose risks. The Marina del Rey lease runs through 2031.
- Innoviva became the controlling shareholder, holding approximately 69–70% of outstanding shares after the placement, according to different passages in the filing; warrant exercise could increase its ownership. This creates governance influence and potential dilution. CFO Steve Martin planned to retire effective June 30, 2022, with Erin Butler appointed to succeed him as principal financial and accounting officer effective July 1.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Disclosure controls were assessed as effective at the reasonable-assurance level.
Most important facts for investors to verify
- Whether the stated runway into Q1 2023 remains valid as clinical, manufacturing and new-facility costs evolve, and whether additional financing is secured.
- Clinical-trial initiation, enrollment and progress for AP-PA02 and AP-SA02, including whether the planned 2022 NCFB Phase 2 trial proceeded.
- The potential dilution and governance implications of Innoviva’s shareholding, warrants and subscription rights.
- Cash requirements, construction progress and lease commitments associated with the Los Angeles facility.
- Whether grant funding, tax rebates, supply availability or COVID-19-related disruptions materially change development plans or liquidity.